nafagrel has been researched along with Coronary Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morishima, Y; Shibano, T; Takahashi, M; Tanaka, T; Watanabe, K | 1 |
| Inoue, H; Kawakubo, K; Murakawa, Y; Nozaki, A; Sugimoto, T; Toda, I; Yoshimoto, N | 1 |
2 other study(ies) available for nafagrel and Coronary Disease
| Article | Year |
|---|---|
Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Coronary Vessels; Diltiazem; Dogs; Enzyme Inhibitors; Female; Heart Rate; Imidazoles; In Vitro Techniques; Male; Nitroglycerin; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrahydronaphthalenes; Thromboxane-A Synthase; Vasodilator Agents | 1995 |
Effects of a thromboxane A2 synthetase inhibitor on ventricular fibrillation threshold during coronary artery occlusion and reperfusion.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Coronary Disease; Coronary Vessels; Dogs; Electrophysiology; Female; Heart Rate; Heart Ventricles; Imidazoles; Ligation; Male; Naphthalenes; Refractory Period, Electrophysiological; Reperfusion; Tetrahydronaphthalenes; Thromboxane B2; Thromboxane-A Synthase; Ventricular Fibrillation | 1990 |